<SEC-DOCUMENT>0000899243-21-003286.txt : 20210126
<SEC-HEADER>0000899243-21-003286.hdr.sgml : 20210126
<ACCEPTANCE-DATETIME>20210126160509
ACCESSION NUMBER:		0000899243-21-003286
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20210126
FILED AS OF DATE:		20210126
DATE AS OF CHANGE:		20210126

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			BridgeBio Pharma, Inc.
		CENTRAL INDEX KEY:			0001743881
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38533
		FILM NUMBER:		21554072

	BUSINESS ADDRESS:	
		STREET 1:		421 KIPLING STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301
		BUSINESS PHONE:		(650) 391-9740

	MAIL ADDRESS:	
		STREET 1:		421 KIPLING STREET
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94301

	FORMER NAME:	
		FORMER CONFORMED NAME:	BridgeBio Pharma LLC
		DATE OF NAME CHANGE:	20180618

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eidos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001731831
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463733671
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		101 MONTGOMERY STREET, SUITE 2550
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
		BUSINESS PHONE:		650-391-9740

	MAIL ADDRESS:	
		STREET 1:		101 MONTGOMERY STREET, SUITE 2550
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94104
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2021-01-26</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001731831</issuerCik>
        <issuerName>Eidos Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>EIDX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001743881</rptOwnerCik>
            <rptOwnerName>BridgeBio Pharma, Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>421 KIPLING STREET</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>PALO ALTO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94301</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2021-01-26</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>14428836</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1000</value>
                    <footnoteId id="F3"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">On January 26, 2021, pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the &quot;Merger Agreement&quot;), by and among BridgeBio Pharma, Inc. (&quot;BridgeBio&quot;), Eidos Therapeutics, Inc. (&quot;Eidos&quot;), Globe Merger Sub I, Inc. (&quot;Merger Sub I&quot;) and Globe Merger Sub II, Inc. (&quot;Merger Sub II&quot;), Merger Sub I merged with and into Eidos (the &quot;Initial Merger&quot;), with Eidos surviving the Initial Merger, and thereafter Eidos merged with and into Merger Sub II (the &quot;Subsequent Merger&quot; and, together with the Initial Merger, the &quot;Mergers&quot;), with Merger Sub II surviving the Subsequent Merger as an indirect and wholly owned subsidiary of BridgeBio under the name &quot;Eidos Therapeutics, Inc.&quot; (the &quot;Surviving Corporation&quot;).</footnote>
        <footnote id="F2">(Continued from footnote 1) At the Effective Time, each share of common stock, par value $0.001 per share, of Eidos (&quot;Eidos Common Stock&quot;) issued and outstanding immediately prior to the Effective Time (subject to certain exceptions) was converted into the right to receive, at the election of each stockholder of Eidos, (A) 1.85 shares of BridgeBio's common stock (&quot;BridgeBio Common Stock&quot;), par value $0.001 per share (the &quot;Stock Consideration&quot;), or (B) $73.26 in cash (the &quot;Cash Consideration&quot;). As of the Effective Time, all shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled, and all shares of Merger Sub I held by BridgeBio Pharma LLC immediately prior to the consummation of the Initial Merger were converted into shares of the Surviving Corporation in the Mergers. As a result of the Mergers, BridgeBio now owns all of the outstanding shares of common stock of the Surviving Corporation.</footnote>
        <footnote id="F3">Calculation of number of shares give effect to the consummation of the Initial Merger described herein, in which shares of Eidos Common Stock issued and outstanding immediately prior to the Effective Time were cancelled and the 1,000 shares of Merger Sub I held by BridgeBio were converted into an aggregate of 1,000 shares of common stock of the Surviving Corporation.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>BridgeBio Pharma, Inc., By: /s/ Neil Kumar, Chief Executive Officer</signatureName>
        <signatureDate>2021-01-26</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
